Cyclofenil in childhood scleroderma

Area of Science:

• Pediatric dermatology
• Rheumatology
• Pharmacology

Background:

• Localized scleroderma is a chronic autoimmune condition affecting the skin.
• Treatment options for pediatric localized scleroderma can be limited.
• Cyclofenil is a drug with potential anti-inflammatory properties.

Observation:

• A 10-year-old girl with localized scleroderma received cyclofenil treatment.
• The treatment duration was nine months.
• Clinical assessment revealed no improvement in the condition.

Findings:

• Cyclofenil demonstrated a lack of efficacy in treating localized scleroderma in this pediatric case.
• Hepatotoxicity was observed as an adverse event, leading to drug discontinuation.
• The study highlights potential safety concerns associated with cyclofenil in children.

Implications:

• This case report suggests cyclofenil may not be an effective treatment for pediatric localized scleroderma.
• Hepatotoxicity is a significant adverse effect to monitor when considering cyclofenil.
• Further research is needed to evaluate the safety and efficacy of cyclofenil in pediatric autoimmune diseases.